Peginterferon and ribavirin treatment for hepatitis C virus infection

被引：49
|
作者：
Tsubota, Akihito [1 ]
Fujise, Kiyotaka [1 ]
Namiki, Yoshihisa [1 ]
Tada, Norio [1 ]
机构：
[1] Jikei Univ, Sch Med, Inst Clin Med & Res, Chiba 2778567, Japan
来源：
WORLD JOURNAL OF GASTROENTEROLOGY | 2011年 / 17卷 / 04期
关键词：
Pegylated interferon alpha; Ribavirin; Chronic hepatitis C virus infection; Difficult-to-treat patient; Individualized treatment; Response-guided therapy; Specifically targeted antiviral therapy for hepatitis C virus; ALPHA-2B PLUS RIBAVIRIN; SUSTAINED VIROLOGICAL RESPONSE; PEGYLATED INTERFERON-ALPHA; CHRONIC HCV INFECTION; RANDOMIZED-TRIAL; HEPATOCELLULAR-CARCINOMA; NAIVE PATIENTS; COMBINATION THERAPY; GENOTYPE-1; PATIENTS; FUSION PROTEIN;
D O I：
10.3748/wjg.v17.i4.419
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Pegylated interferon alpha (IFN alpha) in combination with ribavirin is currently recommended as a standard-of-care treatment for chronic hepatitis C virus (HCV) infection. This combination therapy has drastically improved the rate of sustained virological response, specifically in difficult-to-treat patients. Recently, individualized treatment, such as response-guided therapy, is being developed based on host-, HCV- and treatment-related factors. Furthermore, modified regimens with currently available medications, novel modified IFN alpha and ribavirin or combinations with specifically targeted antiviral therapy for HCV agents, are currently being investigated. The purpose of this review is to address some issues and epoch-making topics in the treatment of chronic HCV infection, and to discuss more optimal and highly individualized therapeutic strategies for HCV-infected patients.
引用
收藏
页码：419 / 432
页数：14
相关论文
共 50 条
  • [21] Efficiency and Safety of an Early Dose Adjustment of Ribavirin in Patients Infected With Hepatitis C Underexposed to the Drug and Treated With Peginterferon Ribavirin
    Loustaud-Ratti, Veronique
    Maynard, Marianne
    Thevenon, Sylvie
    Pradat, Pierre
    Rousseau, Annick
    Alain, Sophie
    Deny, Paul
    Gagnieu, Marie-Claude
    Tran, Albert
    Dao, Thong
    Silvain, Christine
    Lunel-Fabiani, Francoise
    Picard, Nicolas
    Zublena, Iresne
    Marquet, Pierre
    Trepo, Christian
    THERAPEUTIC DRUG MONITORING, 2016, 38 (06) : 684 - 692
  • [22] Laparoscopic splenectomy with peginterferon and ribavirin therapy for patients with hepatitis C virus cirrhosis and hypersplenism
    Akahoshi, Tomohiko
    Tomikawa, Morimasa
    Korenaga, Daisuke
    Ikejiri, Koji
    Saku, Motonori
    Takenaka, Kenji
    SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES, 2010, 24 (03): : 680 - 685
  • [23] AUTOIMMUNE DISORDERS DUE TO DOUBLE ANTIVIRAL THERAPY WITH PEGINTERFERON AND RIBAVIRIN IN PATIENTS WITH HEPATITIS C VIRUS INFECTION
    Docea, Anca Oana
    Gofita, Eliza
    Calina, Daniela
    Ioan, Zaharie Sorin
    Valcea, Daniel Ionica
    Mitrut, Paul
    FARMACIA, 2016, 64 (04) : 605 - 611
  • [24] Grazoprevir plus peginterferon and ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection: a randomized trial
    Lagging, M.
    Brown, A.
    Mantry, P. S.
    Ramji, A.
    Weilert, F.
    Vierling, J. M.
    Howe, A.
    Gendrano, I. N., III
    Hwang, P.
    Zhang, B.
    Wahl, J.
    Robertson, M.
    Mobashery, N.
    JOURNAL OF VIRAL HEPATITIS, 2016, 23 (02) : 80 - 88
  • [25] The study of relationship between neutropenia and infection during treatment with peginterferon α and ribavirin for chronic hepatitis C
    Yu, Jian-Wu
    Sun, Li-Jie
    Zhao, Yong-Hua
    Kang, Peng
    Yan, Bing-Zhu
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2011, 23 (12) : 1192 - 1199
  • [26] RIBAVIRIN AND PEGINTERFERON DOSING IN PATIENTS WITH HEPATITIS C (GENOTYPES 1 AND 4)
    Martin Carmen, Lopez
    Jose Maria, Navarro Jarabo
    Goitia Begona, Tortajada
    Felipe Vicente, Faus
    ATENCION FARMACEUTICA, 2012, 14 (02): : 123 - 128
  • [27] Daclatasvir for the treatment of hepatitis C virus infection
    Adler, Hugh
    Lambert, John S.
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2014, 8 (07) : 725 - 738
  • [28] Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfae
    Liu, Chen-Hua
    Kao, Jia-Horng
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2014, 9 : 2051 - 2067
  • [29] Efficacy and Safety of Peginterferon Alfa-2a and Ribavirin Treatment of Chronic Hepatitis C in the Republic of Serbia
    Bozic, Milena
    Bojovic, Ksenija
    Fabri, Milotka
    Nozic, Darko
    Trkulja, Bojan
    Milosevic, Ivana
    SRPSKI ARHIV ZA CELOKUPNO LEKARSTVO, 2012, 140 (7-8) : 448 - 455
  • [30] The Combination of MK-5172, Peginterferon, and Ribavirin Is Effective in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection Without Cirrhosis
    Manns, Michael P.
    Vierling, John M.
    Bacon, Bruce R.
    Bruno, Savino
    Shibolet, Oren
    Baruch, Yaacov
    Marcellin, Patrick
    Caro, Luzelena
    Howe, Anita Y. M.
    Fandozzi, Christine
    Gress, Jacqueline
    Gilbert, Christopher L.
    Shaw, Peter M.
    Cooreman, Michael P.
    Robertson, Michael N.
    Hwang, Peggy
    Dutko, Frank J.
    Wahl, Janice
    Mobashery, Niloufar
    GASTROENTEROLOGY, 2014, 147 (02) : 366 - +
12345